Background: Based on a phase I study showing the feasibility of combining of oxaliplatin, cisplatin, and 5-fluorouracil (5-FU) (OCF) with radiation therapy (RT) in esophageal cancer, the efficacy of this regimen in esophageal, gastroesophageal (GE), and gastric (G) cancer was assessed in this phase II multicenter study.
with surgery alone [7, 8] . The impact of neoadjuvant chemoradiation on survival depends on achieving a complete pathologic response (pCR) at esophagectomy, which has been reported in 12%-43% of patients treated with neoadjuvant chemoradiotherapy [9] [10] [11] .
To enhance the efficacy of chemotherapy, new cytotoxic drugs have been incorporated into stage IV esophageal and gastric cancer therapy. Oxaliplatin, a third-generation cisplatin analogue, is active in several solid tumor types, including gastric patients failing to cisplatin [12] . Recent studies have evaluated the substitution of cisplatin by oxaliplatin in esophageal and gastric cancer demonstrating similar results in terms of survival and a more favorable safety profile in favor of oxaliplatin [12] . Another potential strategy to enhance chemotherapy effects on gastroesophageal cancer patients is the combination of two platins: oxaliplatin and cisplatin. The rationale for this approach is supported by preclinical data showing that mismatch repair deficiency seems to confer resistance to cisplatin but not to oxaliplatin [13, 14] . Moreover, results of a phase I trial in patients with locally advanced esophageal cancer using the combination of oxaliplatin, cisplatin, and protracted infusion 5-fluorouracil (5-FU) (OCF) with concomitant radiotherapy have been reported [15] . Nineteen patients were treated and two pCR were observed in 12 patients who underwent surgery. Importantly, this schedule was associated with mild toxicity.
Based on these results, our group proceeded to a phase II trial to assess the efficacy of this regimen in patients with esophageal, gastroesophageal, and gastric cancer.
materials and methods

patient eligibility
This multicenter study was conducted at five institutions in Spain. The protocol was approved by the ethics committee of each participating hospital and the study was carried out in accordance with the Declaration of Helsinki. All patients provided written informed consent before enrollment.
Patients (aged 18-75 years) with histologically documented, locally advanced, nonmetastatic esophageal, gastroesophageal, or gastric adenocarcinoma as well as squamous cell carcinoma of the esophagus (T2-4 N0-N+ M0) were eligible. All patients were candidates for curative surgery before entering the study, with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of zero to one, no prior chemotherapy or radiotherapy, and adequate organ function [16] . Exclusion criteria included carcinoma of the cervical esophagus, presence of tracheoesophageal fistula, biopsy-proven invasion of the tracheobronchial tree, and peripheral neuropathy more than grade 1.
pretreatment assessment
Initial evaluation included a detailed clinical history and careful physical examination, recording of concomitant medications, assessment of ECOG PS, hematological and biochemical profiles, and an electrocardiogram. Disease extension was assessed by esophagogastroduodenoscopy; chest radiography; computed tomography (CT) scans of the neck, chest, and abdomen; and endoscopic ultrasonography (EUS). Bronchoscopy was carried out if the tumor was located at or above the level of the carina. Laparoscopic staging was carried out in all patients with adenocarcinoma of the esophagus, gastroesophageal junction, and stomach combined with a T-tube jejunostomy in selected cases. Nutritional counseling was provided in all cases. chemoradiation preoperative treatment /l, neutrophil count <1000 · 10 9 /l with fever, nadir platelet count <25 000, or grade 3-4 nonhematologic toxicity. Radiation therapy was started concomitantly with chemotherapy on day 1 and was delivered with a linear accelerator with 6-18 MV photons. The primary tumor and enlarged lymph nodes were irradiated up to a total dose of 45 Gy (25 fractions of 1.8 Gy each) for esophagus, gastroesophageal junction tumors, and gastric tumors.
Toxic effects were graded according to the National Cancer Institute-Common Toxicity Criteria (version 3.0) and the Radiation Therapy Oncology Group for esophageal toxicity [17, 18] . Those patients who were initially considered resectable and did not experience progressive disease underwent surgical resection. Surgery was scheduled to take place 6-8 weeks after completion of chemoradiotherapy. For mid-esophageal tumors, a three-stage esophagectomy with cervical esophagogastric anastomosis was recommended; for lower esophageal carcinomas, a transthoracic esophagectomy (Ivor Lewis) with two field lymphadenectomy was recommended; for gastroesophageal junction tumors, a transhiatal esophagectomy as well as extended total gastrectomy was allowed; and in patients with gastric carcinomas, a subtotal or total gastrectomy and a D2-lymphadenectomy were recommended depending on the location of the tumor. These procedures were carried out by either open or minimally invasive approach. Surgical complications were defined as any deviation from the normal postoperative course according to the Clavien classification [19] .
pathological assessment
Conventional histopathologic analysis of the resected specimen was done by each center, and the pathologic response was specifically reviewed by a single pathologist (MI) who was blinded for all clinical data. pCR was defined as no viable residual tumor cells (VRTC) at the primary site [20, 21] . Pathologic response to chemoradiotherapy was defined as £10% VRTC.
follow-up
After surgery, patients were assessed every 3 months for the first 2 years and every 6 months thereafter. Each evaluation included a clinical examination and hematological, biochemical, and tumor marker (carcinoembryonic antigen; CA19.9) analyses. A CT scan was obtained every 6 months during the first 2 years and annually thereafter. Treatment failure was defined as any sign of recurrent disease, which could be local, distant, or both. After recurrence, the patients were treated at the investigator's criteria.
statistical analysis
The primary end point was to determine the pCR rate. Secondary study end points included tolerability, completeness of tumor resection (R0 resection versus R1 or R2 resection), the ratio of metastatic to resected lymph nodes [lymph node ratio (LNR)], postoperative morbidity and mortality, the progression-free survival (PFS), and overall survival (OS). The sample size was determined by using the Simon design [22] , assuming an alpha and beta errors of 5% and 20%, respectively. With the assumptions of a response probability of an inactive treatment of 10% and a desired activity Annals of Oncology original articles of the experimental treatment of 25%, a sample size of 43 was required. If three or more pCRs were achieved after the first 13 patients, recruitment was granted to be extended up to 43 patients.
PFS was calculated from the date of study inclusion until the first event (i.e. local recurrence or tumor progression, distant recurrence, or death from any cause). OS was measured from the date of study entry until the date of death irrespective of cause. The probability of survival was estimated using the Kaplan-Meier method, and comparisons were made with the log-rank test [23, 24] . All survival data had been updated to May 2010. Continuous data were compared using the Mann-Whitney U statistic and categorical data using Fisher's exact test. All statistical analyses were carried out at a 0.05 level of significance.
results patient characteristics
Forty-six patients were enrolled from May 2004 to December 2007. Thirty-six patients (78%) were included consecutively from two of the five institutions. Five patients were not eligible for the study (3 patients had peritoneal carcinomatosis, 1 patient with tracheal invasion, 1 patient with mental or social disability), leaving 41 patients in the study (Figure 1 ). The median age was 62 years (range, 39-75 years), and 27% of patients had an ECOG performance scale score of 0. Other baseline patients' characteristics are listed in Table 1 .
preoperative chemoradiotherapy
All eligible patients started chemoradiotherapy treatment. Median duration of treatment was 5 weeks (range, 1-5 weeks). Overall, 37 out of 41 patients completed the planned therapy. The other four patients did not complete the treatment due to disease progression in two cases, treatment-related toxicity in one case, and sudden death in another case. This last patient was a hypertensive male who had a sudden death at home on day 8 after completion of the first chemotherapy cycle. Patient's family refused autopsy, and death was judged as probably nontreatment related.
toxicity Toxicity related to chemoradiation therapy is summarized in Table 2 . Most of the adverse events (AEs) were grade 1 and 2. Apart from fatigue (27%) and neutropenia (14%), the frequency of grade 3 and 4 AEs was <8% for each event. These included diarrhea (7%) and stomatitis (5%). There was one toxic death due to septic shock from respiratory origin in a context of febrile neutropenia. original articles Annals of Oncology (6 patients), treatment-related toxicity (2 patients), patient refusal (1 patient), and nontreatment-related death (1 patient; previously discussed).
Surgical complications are summarized in Table 3 . The overall postoperative mortality was 10% (3 of 31 patients; 2 patient died because of a severe postoperative hemoperitoneum and 1 died because of multiorgan failure secondary to a sepsis of respiratory origin).
A tumor-free (R0) resection was achieved in 29 patients (93.4%). The median number of examined nodes in the 31 resected specimens was 10 (range, 0-37 nodes), with a 12% mean LNR (Table 3) .
pathologic response
Pathologic response (<10% VRTC) was noted in 18 patients (58% of 31 undergoing surgery or 44% of 41 eligible patients). pCR was seen in 9 patients (29% of 31 patients undergoing surgery; 22% of 41 eligible patients). Three pCR cases were observed in gastroesophageal junction/gastric cancer patients (16% of 19 undergoing surgery or 12% of 25 eligible patients) and six pCR in esophageal cancer patients (50% of 12 undergoing surgery or 38% of 16 eligible patients). Four out of the six esophageal cancers with pCR were squamous cell carcinomas. Therefore, among squamous cell carcinoma patients, pCR was achieved in 40% of eligible patients (4 out of 10) and 67% of patients eligible for surgery (4 out of 6) ( with histopathologic response had a significantly lower mean LNR than nonresponders (3% versus 26%, respectively; P = 0.025). , with an estimated 2-year OS of 58% (95% CI 51.4% to 54.6%) (Figure 3 ). Fifteen patients (36%) were still alive, with no evidence of recurrence; one of these patients was a 61-year-old man with an esophageal adenocarcinoma who after completion of chemoradiotherapy refused surgery. Among the 28 patients who survived after the operation, 4 patients developed locoregional extraluminal recurrences, 7 had distant recurrences (liver in 4, central nervous system in 1, peritoneal carcinomatosis in 1, and lung in 1), and 2 had simultaneous locoregional and distant recurrences.
Patients with a histopathologic response (<10% VRTC) had a significantly better OS (P = 0.05; log rank) and PFS (P = 0.006; log rank) than nonresponding patients. Histopathologic responders had a lower recurrence rate [5 of 16 patients (31%); 95% CI 6% to 57%] than nonresponders [8 of 12 (67%); 95% CI 35% to 98%], although the difference was not statistically significant (P = 0.063). Eighty percent (four of five patients) of recurrences in responders were distant, and 20% (one of five patients) were locoregional and distant, while in nonresponders, 38% (three of eight patients) were distant, 50% (four of eight patients) locoregional, and 12% (one of eight patients) locoregional and distant. discussion Treatment of locally advanced gastroesophageal cancer is controversial. The use of neodjuvant chemoradiotherapy is supported by increasing evidence of phase III randomized clinical trials; however, clinical outcome remains poor and new combination strategies are urgently needed. The combination of two platins is supported by preclinical evidence [13, 14, 25] but has poorly been characterized in the clinical setting [26] . After an initial phase I clinical trial, this is the first study that evaluates the efficacy of cisplatin+oxaliplatin combination plus 5-FU and radiotherapy in esophageal and gastric cancer in a formal prospective phase II trial.
Pathological response was observed in 58% of all operated patients, which compares favorably with previously reported trials of neoadjuvant platinum plus fluoropyrimidin-based chemoradiation, although it did not reach the desired 25% of pCR (22% and 29% in the group of patients analyzed by intention to treat and in the group of patients undergoing surgical resection, respectively). Moreover, in terms of resectability and R0 resection rate, our results were similar to previous trials in squamous cell carcinoma of the esophagus [9, 27] and gastroesophageal adenocarcinoma [6, 28] .
One of the most relevant points of the study was the outstanding result in terms of survival, probably due to the therapeutic benefit as well as a through work-up with EUS and laparoscopy. Therefore, the study included a population of accurately assessed and highly selected patients.
Toxicity was acceptable, as the doses of chemotherapy used in the present study had been previously used in a phase I trial [15] . However, two patients died during original articles Annals of Oncology chemoradiation therapy. In addition, there were three deaths after surgery. The rate of postoperative mortality is of concern and could be explained by the multicenter nature of the study. It should be noted that the present scheme was particularly active in patients with esophageal squamous cell carcinoma, with a pCR of 67% in this subgroup. Such an observation has previously been suggested by other trials of oxaliplatin-based chemoradiotherapy in esophageal cancer [29, 30] .
It is of high priority to identify predictive markers of response to chemoradiation, which will help in the selection of locally advanced esophageal and gastric cancer patients most likely to respond to treatment. In this respect, high-grade microsatellite instability (MSI-H) has been linked to cisplatin resistance that can be rescued by oxaliplatin therapy. Although so far there is no strong patient-based evidence of the role of MSI-H as a biomarker of response to platins, it would certainly be interesting to test MSI-H in further studies.
In conclusion, the combination of oxaliplatin, cisplatin, 5-FU, and radiation therapy was confirmed to be a well-tolerated scheme, although there were two deaths during chemoradiotherapy treatment. Activity in terms of pCR was similar to previous studies with conventional 5-FU plus cisplatin-based neoadjuvant chemoradiotherapy, except in esophageal squamous cell carcinomas where it reached higher and promising rates of pCR. It is in this subset of patients were further prospective clinical trials are warranted to assess the efficacy of this combination.
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